estradiol transdermal system

(redirected from Menostar)

estradiol transdermal system,

n brand names: Esbrand, Climera;
drug class: estrogen;
action: increases synthesis of deoxyribonucleic acid, ribonucleic acid, and selected proteins; decreases release of gonadotropin-releasing hormone; inhibits ovulation and helps maintain bone structure;
uses: menopause, prostatic cancer, abnormal uterine bleeding, hypogonadism, ovariectomy, osteoporosis.
References in periodicals archive ?
Food and Drug Administration (FDA) approved Menostar in June 2004.
It is unknown whether this finding applies to younger post-menopausal women or to women taking estrogen alone therapy, such as Menostar.
Menostar should not be used in patients with known hypersensitivity to its ingredients.
Menostar is a clear, dime-sized, once-a-week patch that delivers half the dose-only 14 micrograms per day-of the lowest currently available dose of transdermal estrogen therapy for post-menopausal osteoporosis prevention.
In a two-year clinical study, Menostar, with a very low dose of estrogen, did not increase the risk of endometrial hyperplasia among women with a uterus.
Menostar is an opportunity to serve a growing medical need," said Reinhard Franzen, President and CEO, Berlex Laboratories.
After two years, Menostar increased lumbar spine bone mineral density (BMD) by three percent over baseline (p= <0.
Our study of Menostar showed that with nearly half of the lowest dose of estrogen currently available in a patch for osteoporosis prevention-about one quarter of the standard doses used for osteoporosis prevention-bone density increased to a clinically and statistically significant degree," said Bruce Ettinger, MD, Clinical Professor of Medicine at the University of California, San Francisco and lead investigator the study.
The transdermal delivery for Menostar is made possible through unique 3M Drug Delivery Systems technology.
Upon approval, Menostar will offer healthcare providers with a new treatment option that delivers an ultra-low dose of plant-based estrogen, which will not require a concomitant progestin, even for women with an intact uterus.
In the clinical trials, Menostar was well tolerated; the most common side effects were application site irritation and leukorrhea.